Cargando…

Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Myocardial ischemia/reperfusion (IR) injury represents a critical problem associated with interventional approaches for coronary reperfusion. Pharmacological cardioprotective interventions are advocated to ameliorate IR injury. Melatonin is an anti-inflammatory and antioxidant agent with a wide rang...

Descripción completa

Detalles Bibliográficos
Autores principales: Domínguez-Rodríguez, Alberto, Abreu-González, Pedro, Báez-Ferrer, Néstor, Reiter, Russel J., Avanzas, Pablo, Hernández-Vaquero, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149621/
https://www.ncbi.nlm.nih.gov/pubmed/34055929
http://dx.doi.org/10.3389/fcvm.2021.635083
_version_ 1783697985248428032
author Domínguez-Rodríguez, Alberto
Abreu-González, Pedro
Báez-Ferrer, Néstor
Reiter, Russel J.
Avanzas, Pablo
Hernández-Vaquero, Daniel
author_facet Domínguez-Rodríguez, Alberto
Abreu-González, Pedro
Báez-Ferrer, Néstor
Reiter, Russel J.
Avanzas, Pablo
Hernández-Vaquero, Daniel
author_sort Domínguez-Rodríguez, Alberto
collection PubMed
description Myocardial ischemia/reperfusion (IR) injury represents a critical problem associated with interventional approaches for coronary reperfusion. Pharmacological cardioprotective interventions are advocated to ameliorate IR injury. Melatonin is an anti-inflammatory and antioxidant agent with a wide range of therapeutic properties that may contribute to its cardioprotective effects. No systematic review or meta-analysis has compared melatonin vs. placebo as a cardioprotective agent in humans. The present study, based on a systematic review and meta-analysis, was carried out to assess melatonin's efficacy as a cardioprotective treatment. We performed a systematic review of the available literature. Randomized controlled trials (RCTs) were identified and information was extracted using predefined data extraction forms. The primary outcomes were (a) left ventricular ejection fraction (LVEF) and (b) blood troponin levels in patients who underwent myocardial revascularization and were randomized to melatonin or placebo. The inverse-variance random-effects method was used to pool the estimates. Heterogeneity and publication bias were assessed. Weighted mean differences or standardized mean differences were calculated. A total of 283 records were screened and seven RCTs met all the inclusion criteria. After the pooled analysis, the results on LVEF were consistent across all studies, and a significant heterogeneity was found in the results on troponin levels. The melatonin-treated patients had on average higher LVEF than the placebo-treated individuals with a weighted mean difference = 3.1% (95% CI 0.6–5.5, p = 0.01). Five works compared the levels of troponin after melatonin or placebo treatment. The melatonin-treated patients had lower levels of troponin with a standardized mean difference = −1.76 (95% CI −2.85 to −0.67, p = 0.002). The findings of this meta-analysis revealed that melatonin administration in humans as a cardioprotective agent attenuated heart dysfunction with a favorable effect on the LVEF.
format Online
Article
Text
id pubmed-8149621
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81496212021-05-27 Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Domínguez-Rodríguez, Alberto Abreu-González, Pedro Báez-Ferrer, Néstor Reiter, Russel J. Avanzas, Pablo Hernández-Vaquero, Daniel Front Cardiovasc Med Cardiovascular Medicine Myocardial ischemia/reperfusion (IR) injury represents a critical problem associated with interventional approaches for coronary reperfusion. Pharmacological cardioprotective interventions are advocated to ameliorate IR injury. Melatonin is an anti-inflammatory and antioxidant agent with a wide range of therapeutic properties that may contribute to its cardioprotective effects. No systematic review or meta-analysis has compared melatonin vs. placebo as a cardioprotective agent in humans. The present study, based on a systematic review and meta-analysis, was carried out to assess melatonin's efficacy as a cardioprotective treatment. We performed a systematic review of the available literature. Randomized controlled trials (RCTs) were identified and information was extracted using predefined data extraction forms. The primary outcomes were (a) left ventricular ejection fraction (LVEF) and (b) blood troponin levels in patients who underwent myocardial revascularization and were randomized to melatonin or placebo. The inverse-variance random-effects method was used to pool the estimates. Heterogeneity and publication bias were assessed. Weighted mean differences or standardized mean differences were calculated. A total of 283 records were screened and seven RCTs met all the inclusion criteria. After the pooled analysis, the results on LVEF were consistent across all studies, and a significant heterogeneity was found in the results on troponin levels. The melatonin-treated patients had on average higher LVEF than the placebo-treated individuals with a weighted mean difference = 3.1% (95% CI 0.6–5.5, p = 0.01). Five works compared the levels of troponin after melatonin or placebo treatment. The melatonin-treated patients had lower levels of troponin with a standardized mean difference = −1.76 (95% CI −2.85 to −0.67, p = 0.002). The findings of this meta-analysis revealed that melatonin administration in humans as a cardioprotective agent attenuated heart dysfunction with a favorable effect on the LVEF. Frontiers Media S.A. 2021-05-12 /pmc/articles/PMC8149621/ /pubmed/34055929 http://dx.doi.org/10.3389/fcvm.2021.635083 Text en Copyright © 2021 Domínguez-Rodríguez, Abreu-González, Báez-Ferrer, Reiter, Avanzas and Hernández-Vaquero. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Domínguez-Rodríguez, Alberto
Abreu-González, Pedro
Báez-Ferrer, Néstor
Reiter, Russel J.
Avanzas, Pablo
Hernández-Vaquero, Daniel
Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_fullStr Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_short Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_sort melatonin and cardioprotection in humans: a systematic review and meta-analysis of randomized controlled trials
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149621/
https://www.ncbi.nlm.nih.gov/pubmed/34055929
http://dx.doi.org/10.3389/fcvm.2021.635083
work_keys_str_mv AT dominguezrodriguezalberto melatoninandcardioprotectioninhumansasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT abreugonzalezpedro melatoninandcardioprotectioninhumansasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT baezferrernestor melatoninandcardioprotectioninhumansasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT reiterrusselj melatoninandcardioprotectioninhumansasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT avanzaspablo melatoninandcardioprotectioninhumansasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT hernandezvaquerodaniel melatoninandcardioprotectioninhumansasystematicreviewandmetaanalysisofrandomizedcontrolledtrials